MedTrace Logo

Effect of Riocigaut on Migraine Attack Induction in People With Migraine

NCT05750446 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2024-07-12

No results posted yet for this study

Summary

This double-blind, randomized, placebo-controlled cross-over clinical trial aims to investigate the effects of riocigaut on migraine inducing properties in people with migraine.

Conditions

  • Migraine Without Aura

Interventions

DRUG

Riociguat (BAY 63-2521)

A selective stimulator of soluble guanylate cyclase (sGC)

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Principal Investigators

  • Messoud B Ashina, MD, Phd, DMSc · Danish Headache Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-02-01
Completion
2024-02-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05750446 on ClinicalTrials.gov